FirstHealth of the Carolinas

Clinical Trial Details

Study Title: CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Study Type: Interventional
Study Condition: Lung Cancer
Investigator: Dr. Charles Kuzma
Phone: (910) 715-3500
Research Coordinator: Pam Mason
Phone: (910) 715-2200
Eligibility Criteria: Men or women, ages 18 and older, diagnosed with limited-stage small-cell lung cancer. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Cancer and Leukemia Group B
Study Rationale: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer.
Study Purpose: This randomized phase III trial is comparing three different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.
Study Link: http://clinicaltrials.gov/ct2/show/NCT00632853
   
 
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @ LinkedIn.com
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.